Abstract
Patients with Coronavirus Disease-2019 (COVID‐19) have haemostatic dysfunction and are at higher risk of thrombotic complications. Although age is a major risk factor for outcome impairment in COVID-19, its impact on coagulative patterns here is still unclear. We investigated the association of Endogenous Thrombin Potential (ETP) with thrombotic and haemorrhagic events according to different ages in patients admitted for COVID-19. A total of 27 patients with COVID‐19-related pneumonia, without need for intensive care unit admission or mechanical ventilation at hospital presentation, and 24 controls with non-COVID-19 pneumonia were prospectively included. ETP levels were measured on admission. Patients were evaluated for major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, stroke, transient ischemic attack, venous thromboembolism) and bleeding complications [according to Bleeding Academic Research Consortium (BARC) definition] during in-hospital stay. COVID-19 patients had similar ETP levels compared to controls (AUC 93 ± 24% vs 99 ± 21%, p = 0.339). In the COVID-19 cohort, patients with in-hospital MACE showed lower ETP levels on admission vs those without (AUC 86 ± 14% vs 95 ± 27%, p = 0.041), whereas ETP values were comparable in patients with or without bleeding (AUC 82 ± 16% vs 95 ± 26%, p = 0.337). An interaction between age and ETP levels for both MACE and bleeding complications was observed, where a younger age was associated with an inverse relationship between ETP values and adverse event risk (pint 0.018 for MACE and 0.050 for bleeding). Patients with COVID-19 have similar thrombin potential on admission compared to those with non-COVID-19 pneumonia. In younger COVID-19 patients, lower ETP levels were associated with a higher risk of both MACE and bleeding.
Highlights
Coronavirus Disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) infection, was first reported in December 2019 in China [1]; since it has rapidly become a global pandemic, with a case fatality rate ranging from 2 to 30% according to different age strata and prevalent comorbidities [2, 3]
Demographic characteristics, comorbidities and medical treatments were similar in COVID-19 patients and controls; regarding laboratory data, lymphocytes count was significantly lower, whereas activated partial thromboplastin time (aPTT) and D-dimer levels tended to be higher in the
In patients with COVID-19, those with major adverse cardiovascular events (MACE) (N = 6) during the hospitalization showed higher D-dimer levels on admission (2299, IQR 2010–2467, pg/mL vs 1126, IQR 568–1616, pg/mL, p = 0.010), lower Endogenous Thrombin Potential (ETP) levels (AUC 86 ± 14% vs 95 ± 27%, p = 0.041) and lower C max (97%, IQR 88–105% vs 115%, IQR 97–128%, p = 0.031) vs those without (Table 3)
Summary
Coronavirus Disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) infection, was first reported in December 2019 in China [1]; since it has rapidly become a global pandemic, with a case fatality rate ranging from 2 to 30% according to different age strata and prevalent comorbidities [2, 3]. An advanced age has been associated with a 300-fold increase in the risk of death [4]. Patients hospitalized for COVID-19 usually present a respiratory syndrome, they have a hypercoagulable status and are at higher risk of thrombotic complications [5,6,7]. The impact of aging on coagulation status and events in patients with COVID-19 patients remains unclear
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.